Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
dc.contributor.author | Nolan, Terry | |
dc.contributor.author | Roy-Ghanta, Sumita | |
dc.contributor.author | Montellano, May | |
dc.contributor.author | Weckx, Lily [UNIFESP] | |
dc.contributor.author | Ulloa-Gutierrez, Rolando | |
dc.contributor.author | Lazcano-Ponce, Eduardo | |
dc.contributor.author | Kerdpanich, Angkool | |
dc.contributor.author | Palazzi Safadi, Marco Aurelio | |
dc.contributor.author | Cruz-Valdez, Aurelio | |
dc.contributor.author | Litao, Sandra [UNIFESP] | |
dc.contributor.author | Lim, Fong Seng | |
dc.contributor.author | Mascarenas de Los Santos, Abiel | |
dc.contributor.author | Rodriguez Weber, Miguel Angel | |
dc.contributor.author | Tinoco, Juan-Carlos | |
dc.contributor.author | Hernandez-de Mezerville, Marcela | |
dc.contributor.author | Faingezicht, Idis | |
dc.contributor.author | Kosuwon, Pensri | |
dc.contributor.author | Lopez, Pio | |
dc.contributor.author | Borja-Tabora, Charissa | |
dc.contributor.author | Li, Ping | |
dc.contributor.author | Durviaux, Serge | |
dc.contributor.author | Fries, Louis | |
dc.contributor.author | Dubin, Gary | |
dc.contributor.author | Breuer, Thomas | |
dc.contributor.author | Innis, Bruce L. | |
dc.contributor.author | Vaughn, David W. | |
dc.contributor.institution | Univ Melbourne | |
dc.contributor.institution | GlaxoSmithKline Vaccines | |
dc.contributor.institution | Novavax | |
dc.contributor.institution | Mary Chiles Gen Hosp | |
dc.contributor.institution | De La Salle Hlth Sci Inst | |
dc.contributor.institution | Res Inst Trop Med | |
dc.contributor.institution | Universidade Federal de São Paulo (UNIFESP) | |
dc.contributor.institution | Assoc Fundo Incent Pesquisa | |
dc.contributor.institution | Inst Costarricense Invest Clin | |
dc.contributor.institution | Natl Inst Publ Hlth Mexico | |
dc.contributor.institution | Univ Autonoma Nuevo Leon | |
dc.contributor.institution | Inst Nacl Pediat Mexico | |
dc.contributor.institution | Hosp Gen Durango | |
dc.contributor.institution | Phramongkutklao Hosp | |
dc.contributor.institution | Khon Kaen Univ | |
dc.contributor.institution | Natl Healthcare Grp Polyclin | |
dc.contributor.institution | Ctr Estudios Infect Pediat | |
dc.date.accessioned | 2016-01-24T14:37:43Z | |
dc.date.available | 2016-01-24T14:37:43Z | |
dc.date.issued | 2014-08-15 | |
dc.description.abstract | Background. the vaccine efficacy (VE) of 1 or 2 doses of AS03-adjuvanted influenza A(H1N1) vaccine relative to that of 2 doses of nonadjuvanted influenza A(H1N1) vaccine in children 6 months to <10 years of age in a multinational study conducted during 2010-2011.Methods. A total of 6145 children were randomly assigned at a ratio of 1: 1: 1 to receive 2 injections 21 days apart of A/California/7/2009(H1N1)-AS03 vaccine at dose 1 and saline placebo at dose 2, 2 doses 21 days apart of A/California/7/2009(H1N1)-AS03 vaccine (the Ad2 group), or 2 doses 21 days apart of nonadjuvanted A/California/7/2009(H1N1) vaccine (the NAd2 group). Active surveillance for influenza-like illnesses continued from days 14 to 385. Nose and throat samples obtained during influenza-like illnesses were tested for A/California/7/2009 (H1N1), using reverse-transcriptase polymerase chain reaction. Immunogenicity, reactogenicity, and safety were assessed.Results. There were 23 cases of confirmed 2009 pandemic influenza A(H1N1) (A[H1N1]pdm09) infection for the primary relative VE analysis. the VE in the Ad2 group relative to that in the NAd2 group was 76.8% (95% confidence interval, 18.5%-93.4%). the benefit of the AS03 adjuvant was demonstrated in terms of the greater immunogenicity observed in the Ad2 group, compared with the NAd2 group.Conclusion. the 4-8-fold antigen-sparing adjuvanted pandemic influenza vaccine demonstrated superior and clinically important prevention of A(H1N1)pdm09 infection, compared with nonadjuvanted vaccine, with no observed increase in medically attended or serious adverse events. These data support the use of adjuvanted influenza vaccines during influenza pandemics. | en |
dc.description.affiliation | Univ Melbourne, Murdoch Childrens Res Inst, Carlton, Vic 3010, Australia | |
dc.description.affiliation | Univ Melbourne, Melbourne Sch Populat & Global Hlth, Carlton, Vic 3010, Australia | |
dc.description.affiliation | GlaxoSmithKline Vaccines, King of Prussia, PA USA | |
dc.description.affiliation | Novavax, Rockville, MD USA | |
dc.description.affiliation | Mary Chiles Gen Hosp, Dept Pediat, Manila, Philippines | |
dc.description.affiliation | De La Salle Hlth Sci Inst, Dept Pediat, Dasmarinas City, Philippines | |
dc.description.affiliation | Res Inst Trop Med, Dept Hlth, Muntinlupa, Philippines | |
dc.description.affiliation | Universidade Federal de São Paulo, Dept Pediat, São Paulo, Brazil | |
dc.description.affiliation | Fac Ciencias Med Santa Casa São Paulo, Dept Pediat, São Paulo, Brazil | |
dc.description.affiliation | Assoc Fundo Incent Pesquisa, São Paulo, Brazil | |
dc.description.affiliation | Inst Costarricense Invest Clin, San Jose, Costa Rica | |
dc.description.affiliation | Natl Inst Publ Hlth Mexico, Cuernavaca, Morelos, Mexico | |
dc.description.affiliation | Univ Autonoma Nuevo Leon, Serv Med, Monterrey, Mexico | |
dc.description.affiliation | Inst Nacl Pediat Mexico, Mexico City, DF, Mexico | |
dc.description.affiliation | Hosp Gen Durango, Durango, Mexico | |
dc.description.affiliation | Phramongkutklao Hosp, Infect Dis Unit, Dept Pediat, Bangkok, Thailand | |
dc.description.affiliation | Khon Kaen Univ, Dept Pediat, Fac Med, Khon Kaen, Thailand | |
dc.description.affiliation | Natl Healthcare Grp Polyclin, Singapore, Singapore | |
dc.description.affiliation | Ctr Estudios Infect Pediat, Cali, Colombia | |
dc.description.affiliation | GlaxoSmithKline Vaccines, Wavre, Belgium | |
dc.description.affiliation | GlaxoSmithKline Vaccines, Rixensart, Belgium | |
dc.description.affiliationUnifesp | Universidade Federal de São Paulo, Dept Pediat, São Paulo, Brazil | |
dc.description.source | Web of Science | |
dc.description.sponsorship | GlaxoSmithKline Biologicals | |
dc.format.extent | 545-557 | |
dc.identifier | http://dx.doi.org/10.1093/infdis/jiu173 | |
dc.identifier.citation | Journal of Infectious Diseases. Cary: Oxford Univ Press Inc, v. 210, n. 4, p. 545-557, 2014. | |
dc.identifier.doi | 10.1093/infdis/jiu173 | |
dc.identifier.file | WOS000340243500006.pdf | |
dc.identifier.issn | 0022-1899 | |
dc.identifier.uri | http://repositorio.unifesp.br/handle/11600/38091 | |
dc.identifier.wos | WOS:000340243500006 | |
dc.language.iso | eng | |
dc.publisher | Oxford Univ Press Inc | |
dc.relation.ispartof | Journal of Infectious Diseases | |
dc.rights | Acesso aberto | |
dc.rights.license | http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html | |
dc.subject | H1N1 | en |
dc.subject | pandemic influenza vaccine | en |
dc.subject | influenza virus | en |
dc.subject | Children | en |
dc.subject | efficacy | en |
dc.title | Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial | en |
dc.type | Artigo |
Arquivos
Pacote Original
1 - 1 de 1
Carregando...
- Nome:
- WOS000340243500006.pdf
- Tamanho:
- 587.88 KB
- Formato:
- Adobe Portable Document Format
- Descrição: